LXRX

Lexicon Pharmaceuticals Inc

$2.35
0.02 (0.85%) Today
0.03 (1.22%) After-hours
Compare LXRX
Market Cap
$1.03B+96.6%
Revenue (TTM)
$77.29M+123.1%
Net Income (TTM)
$-31,760,300
EPS (TTM)
-0.07
Shares Out
444.20M
Open
$2.32
Previous Close
$2.34
Day Range
$2.27 – $2.34
52-Week Range
$1.03 – $2.68
Beta
1.05
Volume
1.76M
Avg Volume
3.08M
Exchange
NASDAQ NMS - GLOBAL MARKET

About LXRX

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its mouse gene knockout technology and in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.

Related

News